Bcl2相关髓细胞白血病序列1(MCL1)真核蛋白
Eukaryotic Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT
- 编号EPC615Mu61
- 物种Mus musculus (Mouse，小鼠) 相同的名称，不同的物种。
- 来源真核表达
- 宿主293F cell
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位细胞膜, 细胞核, 线粒体, 细胞质
- 预测分子量19.4kDa
- 实际分子量18kDa(差异分析请参阅说明书)
- 片段与标签Glu152~Gly308 with N-terminal His Tag
- 缓冲液成份PBS, pH7.4, containing 5% Trehalose.
- 性状冻干粉
- 纯度> 90%
- 等电点9.0
-
应用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，请参见活性蛋白。 - 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 暂无报价 暂无报价 暂无报价 暂无报价 暂无报价
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
Figure. SDS-PAGE
-
通过ISO 9001、ISO 13485质量体系认证
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Mus musculus (Mouse，小鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| RPC615Mu01 | Bcl2相关髓细胞白血病序列1(MCL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPC615Mu02 | Bcl2相关髓细胞白血病序列1(MCL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPC615Mu61 | Bcl2相关髓细胞白血病序列1(MCL1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC615Mu01 | Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体 | WB; IHC; ICC; IP. |
| PAC615Mu02 | Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体 | WB; IHC; ICC; IP. |
| SEC615Mu | Bcl2相关髓细胞白血病序列1(MCL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC615Mu | Bcl2相关髓细胞白血病序列1(MCL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
| ACTA NEUROPATHOLOGICA COMMUNICATIONS | Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma [Pubmed: 32410663] |
| Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 [33540760] |
留言咨询
